Artivion, Inc. (AORT) Stock Price & Analysis
Artivion, Inc. (AORT) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $18.16 (-2.00%), as of the Nov 20, 2026 trading session; market cap $886M.
Educational signal · not a buy or sell recommendation · How to read this
Artivion, Inc. · AORT · NYSE
Artivion, Inc. specializes in manufacturing and distributing medical devices and implantable human tissues, primarily for cardiac, vascular, and thoracic surgical procedures. Their product portfolio includes surgical grafts, valves, and fixation devices.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Artivion (AORT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Slipping.
- quarterly revenue $124M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 2 of the last 8 reports
- Altman Z 1.63 · Piotroski F 3
Holding back: balance-sheet strain
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $18.16 | |
| Change on the day | -2.00% | |
| 52-week range | $18.16 – $48.25 | |
| Market capitalisation | $886M | — |
| Price / earnings (trailing) | 87.92 | |
| Shares traded on the day | 642.1K |
Price & events
Other perspectives
Council score for Artivion (AORT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Artivion (AORT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Artivion, Inc. (AORT) is listed on NYSE. It employs 1,800 people and is led by James Patrick Mackin. In Q3 FY2026 it reported revenue of $124M and net income of -$8M. The market values it at $886M.
What do the latest results show for Artivion (AORT)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $124M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $124M | -$8M | -$0.16 (diluted) |
| Q2 FY2026 | $126M | -$14M | -$0.28 (diluted) |
| Q1 FY2026 | $116M | $1M | $0.03 (diluted) |
| Q4 FY2025 | $116M | $2M | $0.05 (diluted) |
What are the financial strengths and risks for Artivion (AORT)?
Short answer · as of
The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 1.63 · Piotroski F 3. Trailing ratios: ROE -3.9% · ROA -1.7% · current ratio 4.42 · earnings yield -1.9% · free-cash-flow yield -4.8%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.63 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-3.9%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
What should you watch next at Artivion (AORT)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Artivion compare with its peers?
Short answer
Artivion's score ranks tied for 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $81.02 Nov 20, 2026 | $1.04B | 94 5-pillar Nov 18, 2026 | |
| $18.79 Nov 20, 2026 | $654M | 94 5-pillar Nov 18, 2026 | |
| $12.42 Nov 20, 2026 | $715M | 92 5-pillar Nov 18, 2026 | |
| $25.60 Nov 20, 2026 | $573M | 90 5-pillar Nov 18, 2026 | |
| $9.95 Nov 19, 2026 | $681M | 79 5-pillar Nov 18, 2026 | |
| $46.56 Nov 20, 2026 | $1.39B | 79 5-pillar Nov 18, 2026 | |
| $13.25 Nov 20, 2026 | $1.03B | 68 5-pillar Nov 18, 2026 | |
| $18.10 Nov 20, 2026 | $769M | 62 5-pillar Nov 18, 2026 | |
| $26.71 Nov 20, 2026 | $4.65B | 50 5-pillar Nov 18, 2026 | |
| $23.73 Nov 20, 2026 | $1.07B | 39 5-pillar Nov 18, 2026 | |
| $31.74 Nov 20, 2026 | $829M | 37 5-pillar Nov 18, 2026 | |
| Artivion (AORT) — this page | $18.16 | $886M | 34 |
| $10.18 Nov 20, 2026 | $566M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $30.00 – $45.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $35.33
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $31.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 10, 2026
- Transactions
- 15
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 9
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AORT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AORT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Artivion (AORT)?
- AORT Q3 2026 deep dive: stent graft growth and NEXUS launch preparations shape outlook
- Artivion (AORT) Stock Looks About Right Following Nexus Launch Preparations
- Is Artivion (AORT) Undervalued Following Mixed Earnings And A Return To Losses?
- Canaccord Genuity Maintains Buy on Artivion, Lowers Price Target to $30
Investor Questions: AORT Stock
These answers are editorial: 1 of these 9 answers is drawn from the AORT research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AORT?
AORT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is AORT a good stock to buy?
Stock Expert AI does not rate AORT buy, sell or hold. Artivion, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AORT stock price today?
The last price recorded for Artivion, Inc. (AORT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AORT price target?
The last analyst consensus price target we captured for Artivion, Inc. (AORT), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the main risks for AORT?
The main risks for Artivion include product liability claims and recalls, which can impact brand reputation and financial performance. Economic downturns can affect healthcare spending and demand for elective surgical procedures. Intense competition from established medical device companies poses a threat to market share.
What are the key factors to evaluate for AORT?
Artivion, Inc. (AORT) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. The timeline for emerging market penetration is ongoing, with a long-term focus on building sustainable growth. Not financial advice.
How frequently does AORT data refresh on this page?
AORT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AORT's recent stock price performance?
Artivion, Inc. (AORT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio catering to various surgical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AORT overvalued or undervalued right now?
The trailing P/E of Artivion, Inc. (AORT) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com